Other Information.
−Removed: On May 1, 2023, the Company’s Board of Directors appointed Dr.
−Removed: Kumar Budur as the Company’s new Chief Medical Officer following the appointment of Dr.
−Removed: Jeffrey Dayno as the Company’s President and Chief Executive Officer on April 24, 2023.
−Removed: Budur has served in the role of SVP & Head of Clinical Development with the Company since March 21, 2022.
−Removed: Prior to joining Harmony Biosciences, Dr.
−Removed: Budur spent 6 years at each of AbbVie Inc.
−Removed: and Takeda Pharmaceutical Company, respectively.
−Removed: A nationally recognized expert in Research and Development, he has overseen programs ranging from late discovery, early clinical development to late clinical development, and post-marketing studies.
−Removed: He has experience in progressing small molecules, biologics, and drug-device combinations through various stages of development.
−Removed: Budur was involved with four New Drug Applications (NDAs) and was the lead for the registration of clinical trials, submission, and approval processes of two NDAs.
−Removed: Budur was trained at Cambridge University in the UK and Cleveland Clinic in the US and completed his residency in Psychiatry and fellowships in Neurophysiology and Sleep Medicine.
−Removed: He is Board Certified in Psychiatry and Sleep Medicine and holds a master’s degree in clinical research from Case Western Reserve University.
−Removed: Budur has published over 45 original research papers in peer reviewed journals, edited four books, and chaired National and International seminars and symposiums.
Incorporated by Reference
4 unchanged sentences
August 21, 2020
+Added: Executive Employment Agreement dated April 24, 2023, between Harmony Biosciences, LLC and Jeffrey M.
+Added: April 24, 2023
Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following financial statements from the Company ’ s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 formatted in Inline XBRL:
+Added: The following financial statements from the Company ’ s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 formatted in Inline XBRL:
(i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Stockholders ’ Equity and (vi) Notes to Financial Statements, tagged as blocks of text and including detailed tags.
9 unchanged sentences
President, Chief Executive Officer and Director (principal executive officer)
+Added: August 1, 2023
/s/ Sandip Kapadia
1 unchanged sentence
Chief Financial Officer (principal financial officer)
+Added: August 1, 2023
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.